Table 1. Total and background factor-based Felis catus papillomavirus 2 PCR results of analyzed samples from Taiwan and Japan.
| Taiwan | Japan | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FcaPV2 PCR | FcaPV2 PCR | ||||||||||
| E1 single-positive | E7 single-positive | E1/E7 double-positive | E1 and/or E7-positive | Negative | E1 single-positive | E7 single-positive | E1/E7 double-positive | E1 and/or E7-positive | Negative | ||
| ACTB-positive samples (n=49) | 14.3 (7/49) | 12.2 (6/49) | 20.4 (10/49) | 46.9 (23/49)* | 53.1 (26/49) | ACTB-positive samples (n=35) | 2.9 (1/35) | 0 (0/35) | 5.7 (2/35) | 8.6 (3/35)* | 91.4 (32/35) |
| Background factors | |||||||||||
| Age | Age | ||||||||||
| <5 (n=2) | 0 (0/2) | 0 (0/2) | 50.0 (1/2) | 50.0 (1/2) | 50.0 (1/2) | <5 (n=0) | - | - | - | - | - |
| 5–10 (n=12) | 25.0 (3/12) | 0 (0/12) | 25.0 (3/12) | 50.0 (6/12) | 50.0 (6/12) | 5–10 (n=9) | 0 (0/9) | 0 (0/9) | 11.1 (1/9) | 11.1 (1/9) | 88.9 (8/9) |
| >10 (n=32) | 9.4 (3/32) | 15.6 (5/32) | 18.8 (6/32) | 43.8 (14/32) | 56.3 (18/32) | >10 (n=26) | 3.8 (1/26) | 0 (0/26) | 3.8 (1/26) | 7.7 (2/26) | 92.3 (24/26) |
| Unknown (n=3) | 33.3 (1/3) | 33.3 (1/3) | 0 (0/3) | 66.7 (2/3) | 33.3 (1/3) | ||||||
| Sex | Sex | ||||||||||
| M (n=3) | 0 (0/3) | 33.3 (1/3) | 0 (0/3) | 33.3 (1/3) | 66.7 (2/3) | M (n=7) | 0 (0/7) | 0 (0/7) | 14.3 (1/7) | 14.3 (1/7) | 71.4 (5/7) |
| MX (n=21) | 4.8 (1/21) | 19.0 (4/21) | 19.0 (4/21) | 42.3 (9/21) | 57.1 (12/21) | MX (n=9) | 0 (0/9) | 0 (0/9) | 0 (0/9) | 0 (0/9) | 100 (9/9) |
| F (n=8) | 12.5 (1/8) | 0 (0/8) | 25.0 (2/8) | 37.5 (3/8) | 62.5 (5/8) | F (n=4) | 0 (0/4) | 0 (0/4) | 0 (0/4) | 0 (0/4) | 100 (4/4) |
| FX (n=15) | 66.7 (4/15) | 6.7 (1/15) | 26.7 (4/15) | 60.0 (9/15) | 40.0 (6/15) | FX (n=15) | 5.9 (1/15) | 0 (0/15) | 6.7 (1/15) | 13.3 (2/15) | 86.7 (13/15) |
| Unknown (n=2) | 50.0 (1/2) | 0 (0/2) | 50.0 (1/2) | 100 (2/2) | 0 (0/2) | ||||||
| Lesion site | Lesion site | ||||||||||
| Cutaneous (n=19) | 10.5 (2/19) | 5.3 (1/19) | 21.1 (4/19) | 36.8 (7/19) | 63.2 (12/19) | Cutaneous (n=21) | 4.8 (1/21) | 0 (0/21) | 4.8 (1/21) | 9.2 (2/21) | 90.5 (19/21) |
| Mucosal (Oral) (n=19) | 15.8 (3/19) | 21.1 (4/19) | 21.1 (4/19) | 57.9 (11/19) | 42.1 (8/19) | Mucosal (Oral) (n=9) | 0 (0/9) | 0 (0/9) | 11.1 (1/9) | 11.1 (1/9) | 88.9 (8/9) |
| Mucosal (Non-oral) (n=10) | 20.0 (2/10) | 10.0 (1/10) | 20.0 (2/10) | 50.0 (5/10) | 50.0 (5/10) | Mucosal (Non-oral) (n=5) | 0 (0/5) | 0 (0/5) | 0 (0/5) | 0 (0/5) | 100 (5/5) |
| Unknown (n=1) | 0 (0/1) | 0 (0/1) | 0 (0/1) | 0 (0/1) | 100 (1/1) | ||||||
PCR-positive ratio (%) and sample numbers of Taiwan- and Japan-derived SCC lesions are shown. Details and PCR results of each case are listed in Supplementary Table 1. ACTB, beta-actin; F, female; FX, neutered female; M, male; MX, neutered male. *Statistically significant difference between Taiwan and Japan (P<0.01), Fisher’s extract two-sided test.